DESVENLAFAXINE SUCCINATE (Pristiq Extended-Release)
DESVENLAFAXINE SUCCINATE risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Pristiq Extended-Release.
DESVENLAFAXINE SUCCINATE (brand names: Pristiq Extended-Release) is classified as Low risk (2 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. FDA approved in the United States. SNRI antidepressant with moderate risk due to serotonin syndrome potential and withdrawal effects.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (2 points)
- Serotonergic: Risk of serotonin syndrome when combined with other serotonergic drugs
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
| United States (FDA) | Rx only | FDA approved |
Risk Profile
SNRI antidepressant with moderate risk due to serotonin syndrome potential and withdrawal effects.
Regulatory and Compliance Guidance
When DESVENLAFAXINE SUCCINATE appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
United Kingdom NICE / MHRA / FPM
NICE guidelines recommend certain antidepressants (amitriptyline, duloxetine) for chronic pain management. For personal injury claims, antidepressant prescribing should be assessed for injury relatedness.
United States FDA / CDC / State WC
FDA approved for use in the United States.
FDA Boxed Warning: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1) ] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1) ] . PRISTIQ is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased the risk of suicidal thoughts and behaviors in children, adolescents and young adults taking antidepressants ( 5.1 ). • Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). • PRISTIQ is not approved for use in pediatric patients ( 8.4 ).
Need to assess this medication across your caseload?
Run a full risk assessment including DESVENLAFAXINE SUCCINATE interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.